T
Transcera develops a novel therapeutic platform that utilizes sphingolipid biology to induce extracellular protein degradation. This approach combines a proprietary lysosome-targeting lipid, linker, and binder to create compact molecules capable of degrading diverse soluble and membrane proteins. The platform enables potent, selective, and systemic degradation for treating chronic diseases driven by aberrant extracellular biology.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Transcera develops a novel therapeutic platform that utilizes sphingolipid biology to induce extracellular protein degradation. This approach combines a proprietary lysosome-targeting lipid, linker, and binder to create compact molecules capable of degrading diverse soluble and membrane proteins. The platform enables potent, selective, and systemic degradation for treating chronic diseases driven by aberrant extracellular biology.